June 28, 2024 03:19 PM EDTUpdated 05:37 PM

Federal grand jury indicts Cassava collaborator for allegedly defrauding NIH

Zachary Brennan

Senior Editor

A Maryland federal grand jury on Thursday indicted neuroscientist Hoau-Yan Wang, a longtime Cassava Sciences collaborator, for allegedly defrauding the NIH out of about …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Federal grand jury indicts Cassava collaborator for allegedly defrauding NIH

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

Fed­er­al grand ju­ry in­dicts Cas­sa­va col­lab­o­ra­tor for al­leged­ly de­fraud­ing NIH

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

Federal grand jury indicts Cassava collaborator for allegedly defrauding NIH

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B